{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:49:31Z","timestamp":1788922171697,"version":"build-2803163510"},"reference-count":91,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"unspecified","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institutes on Drug Abuse","doi-asserted-by":"crossref","award":["R01 DA-050629"],"award-info":[{"award-number":["R01 DA-050629"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,4,26]]},"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Urine drug tests (UDTs) are commonly used for monitoring opioid agonist treatment (OAT) responses, supporting the clinical decision for take-home doses and monitoring potential diversion. However, there is limited evidence supporting the utility of mandatory UDTs\u2014particularly the impact of UDT frequency on OAT retention. Real-world evidence can inform patient-centred approaches to OAT and improve current strategies to address the ongoing opioid public health emergency. Our objective is to determine the safety and comparative effectiveness of alternative UDT monitoring strategies as observed in clinical practice among OAT clients in British Columbia, Canada from 2010 to 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>We propose a population-level retrospective cohort study of all individuals 18 years of age or older who initiated OAT from 1 January 2010 to 17 March 2020. The study will draw on eight linked health administrative databases from British Columbia. Our primary outcomes include OAT discontinuation and all-cause mortality. To determine the effectiveness of the intervention, we will emulate a \u2018per-protocol\u2019 target trial using a clone censoring approach to compare fixed and dynamic UDT monitoring strategies. A range of sensitivity analyses will be executed to determine the robustness of our results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The protocol, cohort creation and analysis plan have been classified and approved as a quality improvement initiative by Providence Health Care Research Ethics Board and the Simon Fraser University Office of Research Ethics. Results will be disseminated to local advocacy groups and decision-makers, national and international clinical guideline developers, presented at international conferences and published in peer-reviewed journals electronically and in print.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-068729","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T11:30:13Z","timestamp":1685532613000},"page":"e068729","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Comparative effectiveness of urine drug screening strategies alongside opioid agonist treatment in British Columbia, Canada: a population-based observational study protocol"],"prefix":"10.1136","volume":"13","author":[{"given":"B Carolina","family":"Guerra-Alejos","sequence":"first","affiliation":[{"name":"Centre for Health Evaluation and Outcome Sciences, Vancouver, British Columbia, Canada"},{"name":"Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Kurz","sequence":"additional","affiliation":[{"name":"Centre for Health Evaluation and Outcome Sciences, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Eun","family":"Min","sequence":"additional","affiliation":[{"name":"Centre for Health Evaluation and Outcome Sciences, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M","family":"Dale","sequence":"additional","affiliation":[{"name":"Centre for Health Evaluation and Outcome Sciences, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micah","family":"Piske","sequence":"additional","affiliation":[{"name":"Centre for Health Evaluation and Outcome Sciences, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paxton","family":"Bach","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bruneau","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Emergency Medicine, University of Montreal, Montreal, Qu\u00e9bec, Canada"},{"name":"Research Center, Centre hospitalier de l'Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2375-5006","authenticated-orcid":false,"given":"Paul","family":"Gustafson","sequence":"additional","affiliation":[{"name":"Department of Statistics, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X Joan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Statistics and Actuarial Science, Simon Fraser University, Burnaby, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Kampman","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P Todd","family":"Korthuis","sequence":"additional","affiliation":[{"name":"School of Public Health, OHSU-PSU, Portland, Oregon, USA"},{"name":"Section of Addiction Medicine, Oregon Health & Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Loughin","sequence":"additional","affiliation":[{"name":"Department of Statistics and Actuarial Science, Simon Fraser University, Burnaby, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Maclure","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Pharmacology and Therapeutics, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W","family":"Platt","sequence":"additional","affiliation":[{"name":"Departments of Epidemiology, Biostatistics, and Occupational Health and of Pediatrics, McGill University, Montreal, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Siebert","sequence":"additional","affiliation":[{"name":"Center for Health Decision Science, Department of Health Policy and Management, Harvard University T H Chan School of Public Health, Boston, Massachusetts, USA"},{"name":"Department of Public Health, Health Services Research and Health Technology Assessment, Private University of Health Sciences Medical Informatics and Technology Hall\/Tyrol Institute for Health Information Systems, Hall in Tirol, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Eugenia","family":"Soc\u00edas","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Wood","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2513-3718","authenticated-orcid":false,"given":"Bohdan","family":"Nosyk","sequence":"additional","affiliation":[{"name":"Centre for Health Evaluation and Outcome Sciences, Vancouver, British Columbia, Canada"},{"name":"Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"2025121220304263000_13.5.e068729.1","unstructured":"British Columbia Centre on Substance Use, BC Ministry of Health, Ministry of Mental Health and Addictions . Urine drug testing in patients prescribed opioid agonist treatment\u2014 breakout resource. 2021."},{"key":"2025121220304263000_13.5.e068729.2","first-page":"1","article-title":"Appropriate use of drug testing in clinical addiction medicine","volume":"11()","year":"2017","journal-title":"J Addict Med"},{"key":"2025121220304263000_13.5.e068729.3","unstructured":"Center for Addiction and Mental Health . Opioid agonist therapy: a synthesis of Canadian guidelines for treating opioid use disorder. 2021."},{"key":"2025121220304263000_13.5.e068729.4","unstructured":"British Columbia Centre on Substance Use, B. C. Ministry of Health . A guideline for the clinical management of opioid use disorder. British Columbia Center on Substance Use, 2017."},{"key":"2025121220304263000_13.5.e068729.5","unstructured":"Canadian Research Initiative in Substance Misuse . CRISM National guideline for the clinical management of opioid use disorder. Canadian Institutes on Health Research, 2018."},{"key":"2025121220304263000_13.5.e068729.6","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000668"},{"key":"2025121220304263000_13.5.e068729.7","unstructured":"Ling W , Stephenson D , Vasti E . Guidelines for physicians working in California opioid treatment programs. California Society of Addiction Medicine, 2019."},{"key":"2025121220304263000_13.5.e068729.8","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000323"},{"key":"2025121220304263000_13.5.e068729.9","unstructured":"Substance Abuse and Mental Health Services Administration . Clinical drug testing in primary care. Technical assistance publication (TAP) 32. Substance Abuse and Mental Heath Services Administration, 2012."},{"key":"2025121220304263000_13.5.e068729.10","unstructured":"Substance Abuse and Mental Health Services Administration . Telehealth for the Treatment of Serious Mental Illness and Substance Use Disorders. Substance Abuse and Mental Heath Services Administration, 2021."},{"key":"2025121220304263000_13.5.e068729.11","unstructured":"Clinical Guidelines on Drug Misuse and Dependence, Update 2017 Independent Expert Working Group . Drug misuse and dependence: UK guidelines on clinical management. Global and Public Health \/ Population Health \/ Healthy Behaviours, 2017."},{"key":"2025121220304263000_13.5.e068729.12","unstructured":"National Institute for Health and Care Excellence . Opioid dependence | CKS | NICE. National Institute on Health and Care Excellence, 2022."},{"key":"2025121220304263000_13.5.e068729.13","unstructured":"New South Wales Ministry of Health . NSW clinical guidelines: treatment of opioid dependence - 2018. NSW Ministry of Health, 2018."},{"key":"2025121220304263000_13.5.e068729.14","unstructured":"Western Australia Community Pharmacotherapy Program, Community Program for Opioid Pharmacotherapy Management Committee . Clinical policies and procedures for the use of methadone and buprenorphine in the treatment of opioid dependence. Government of Western Australia Alcohol and Drug Authority, 2014."},{"key":"2025121220304263000_13.5.e068729.15","unstructured":"Ministry of Health . New Zealand practice guidelines for opioid substitution treatment. 2014."},{"key":"2025121220304263000_13.5.e068729.16","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 . Strat\u00e9gies th\u00e9rapeutiques pour les personnes d\u00e9pendantes des opiac\u00e9s: place des traitements de substitution. Report No.: 07554982 Contract No.: 18. 2004."},{"key":"2025121220304263000_13.5.e068729.17","unstructured":"Substance Abuse and Mental Health Services Administration . TIP 63: medications for opioid use disorder. Substance Abuse and Mental Heath Services Administration, 2021."},{"key":"2025121220304263000_13.5.e068729.18","unstructured":"Gowing L , Ali R , Dunlop A , et al . National guidelines for medication-assisted treatment of opioid dependence. Commonwealth of Australia, 2014."},{"key":"2025121220304263000_13.5.e068729.19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/jalm\/jfab095","article-title":"Comparative analyses of three point-of-care urine drug test devices' performance characteristics for use in ambulatory clinic settings","volume":"7","author":"Waggoner","year":"2022","journal-title":"J Appl Lab Med"},{"key":"2025121220304263000_13.5.e068729.20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.36076\/ppj.2011\/14\/175","article-title":"Comparative evaluation of the accuracy of immunoassay with liquid chromatography Tandem mass Spectrometry (LC\/MS\/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients","volume":"3;14","author":"Manchikanti","year":"2011","journal-title":"Pain Phys"},{"key":"2025121220304263000_13.5.e068729.21","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkw088"},{"key":"2025121220304263000_13.5.e068729.22","first-page":"SE1","article-title":"Immunoassay-based drug tests are inadequately sensitive for medication compliance monitoring in patients treated for chronic pain","volume":"20","author":"Snyder","year":"2017","journal-title":"Pain Physician"},{"key":"2025121220304263000_13.5.e068729.23","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1533-2500.2010.00375.x","article-title":"The role of urine drug testing for patients on opioid therapy","volume":"10","author":"Pergolizzi","year":"2010","journal-title":"Pain Practice"},{"key":"2025121220304263000_13.5.e068729.24","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.5858\/arpa.2020-0055-RA","article-title":"Point-of-care drug of abuse testing in the opioid epidemic","volume":"144","author":"Li","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"2025121220304263000_13.5.e068729.25","first-page":"33","article-title":"Urine drug tests: ordering and interpreting results","volume":"99","author":"Kale","year":"2019","journal-title":"Am Fam Physician"},{"key":"2025121220304263000_13.5.e068729.26","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-021-11757-x","article-title":"Towards cross-Canada monitoring of the unregulated Street drug supply","volume":"21","author":"Biggar","year":"2021","journal-title":"BMC Public Health"},{"key":"2025121220304263000_13.5.e068729.27","doi-asserted-by":"crossref","DOI":"10.1186\/s12954-015-0088-4","article-title":"Why the FUSS (fentanyl urine screen study)? A cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia, Canada","volume":"12","author":"Amlani","year":"2015","journal-title":"Harm Reduct J"},{"key":"2025121220304263000_13.5.e068729.28","unstructured":"Payer DE , Young MM , Maloney-Hall B , et al . Adulterants, Contaminants and Co-occurring substances in drugs on the illegal market in Canada: an analysis of data from drug seizures, drug checking and urine toxicology. Ottawa, Ontario. 2020."},{"key":"2025121220304263000_13.5.e068729.29","unstructured":"College of Physicians and Surgeons of British Columbia . Methadone maintenance program: clinical practice guideline 2015. n.d. Available: http:\/\/www.bccdc.ca\/resource-gallery\/Documents\/Statistics%20and%20Research\/Publications\/Epid\/Other\/02_CPSBC-Methadone_Maintenance_Program_Clinical%20_Practice_Guideline.pdf"},{"key":"2025121220304263000_13.5.e068729.30","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16070792"},{"key":"2025121220304263000_13.5.e068729.31","doi-asserted-by":"crossref","unstructured":"Amato L , Minozzi S , Davoli M , et al . Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 2011. doi:10.1002\/14651858.CD004147.pub4","DOI":"10.1002\/14651858.CD004147.pub4"},{"key":"2025121220304263000_13.5.e068729.32","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.ADM.0000435321.39251.d7","article-title":"Safe methadone induction and stabilization","volume":"7","author":"Baxter","year":"2013","journal-title":"J Addict Med"},{"key":"2025121220304263000_13.5.e068729.33","first-page":"e194","article-title":"Opioid use disorder in primary care: PEER umbrella systematic review of systematic reviews","volume":"65","author":"Korownyk","year":"2019","journal-title":"Can Fam Physician"},{"key":"2025121220304263000_13.5.e068729.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2013.12.009"},{"key":"2025121220304263000_13.5.e068729.35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drugpo.2018.08.006","article-title":"Lacking evidence for the association between frequent urine drug screening and health outcomes of persons on opioid agonist therapy","volume":"64","author":"McEachern","year":"2019","journal-title":"Int J Drug Policy"},{"key":"2025121220304263000_13.5.e068729.36","doi-asserted-by":"crossref","unstructured":"Nielsen S , Larance B , Degenhardt L , et al . Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev 2016:CD011117. doi:10.1002\/14651858.CD011117.pub2","DOI":"10.1002\/14651858.CD011117.pub2"},{"key":"2025121220304263000_13.5.e068729.37","unstructured":"Wells C , Felipe E . Drug testing for patients with substance use disorder: clinical effectiveness and guidelines. Canadian Agency for Drugs and Technologies in Health (CADTH)), 2017."},{"key":"2025121220304263000_13.5.e068729.38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.drugalcdep.2018.08.010","article-title":"Opioid and cocaine use among primary care patients on buprenorphine-self-report and urine drug tests","volume":"192","author":"Bagley","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"2025121220304263000_13.5.e068729.39","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103768","article-title":"Consensus recommendations for opioid agonist treatment following the introduction of emergency clinical guidelines in Ireland during the COVID-19 pandemic: a national Delphi study","volume":"106","author":"Durand","year":"2022","journal-title":"Int J Drug Policy"},{"key":"2025121220304263000_13.5.e068729.40","unstructured":"DiBenedetto DJ , Wawrzyniak KM , Schatman ME , et al . Increased frequency of urine drug testing in chronic opioid therapy: rationale for strategies for enhancing patient adherence and safety"},{"key":"2025121220304263000_13.5.e068729.41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/pm\/pnx285","article-title":"Rational urine drug monitoring in patients receiving opioids for chronic pain: consensus recommendations","volume":"19","author":"Argoff","year":"2018","journal-title":"Pain Med"},{"key":"2025121220304263000_13.5.e068729.42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186315","article-title":"Primary care models for treating opioid use disorders: what actually works? A systematic review","volume":"12","author":"Lagisetty","year":"2017","journal-title":"PLoS One"},{"key":"2025121220304263000_13.5.e068729.43","unstructured":"BC Coroners Service & BC Ministry of Health . Preventing pharmaceutical opioid-associated mortality in British Columbia: A review of prescribed opioid overdose deaths, 2009-2013. 2017. Available: https:\/\/www2.gov.bc.ca\/assets\/gov\/birth-adoption-death-marriage-and-divorce\/deaths\/coroners-service\/statistical\/pharmaceutical-opioid-mortality.pdf"},{"key":"2025121220304263000_13.5.e068729.44","unstructured":"BC Coroners\u00a0Service . BC Coroners service death review panel: a review of illicit drug overdoses. 2018. Available: https:\/\/www2.gov.bc.ca\/assets\/gov\/birth-adoption-death-marriage-and-divorce\/deaths\/coroners-service\/death-review-panel\/bccs_illicit_drug_overdose_drp_report.pdf"},{"key":"2025121220304263000_13.5.e068729.45","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/jamapsychiatry.2022.1776","article-title":"Methadone-involved overdose deaths in the US before and after Federal policy changes expanding take-home methadone doses from opioid treatment programs","volume":"79","author":"Jones","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"2025121220304263000_13.5.e068729.46","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2012.0846"},{"key":"2025121220304263000_13.5.e068729.47","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jsat.2018.01.005","article-title":"Expected and actual fentanyl exposure among persons seeking opioid withdrawal management","volume":"86","author":"Kenney","year":"2018","journal-title":"J Subst Abuse Treat"},{"key":"2025121220304263000_13.5.e068729.48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jsat.2017.01.004","article-title":"Characterizing fentanyl use in methadone-maintained clients","volume":"75","author":"Arfken","year":"2017","journal-title":"J Subst Abuse Treat"},{"key":"2025121220304263000_13.5.e068729.49","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102665","article-title":"Known fentanyl use among clients of harm reduction sites in British Columbia, Canada","volume":"77","author":"Karamouzian","year":"2020","journal-title":"Int J Drug Policy"},{"key":"2025121220304263000_13.5.e068729.50","unstructured":"Government of British Columbia . Responding to British Columbia\u2019s drug poisoning crisis. 2021."},{"key":"2025121220304263000_13.5.e068729.51","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.15425","article-title":"Analysis of urine drug test results from substance use disorder treatment practices and overdose mortality rates, 2013-2020","volume":"5","author":"Whitley","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025121220304263000_13.5.e068729.52","unstructured":"United States Drug Enforcement Administration . 2020 National drug threat assessment. US Department of Justice. 2021."},{"key":"2025121220304263000_13.5.e068729.53","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1080\/08897077.2021.1946892","article-title":"Increasing preference for fentanyl among a cohort of people who use opioids in Vancouver, Canada, 2017-2018","volume":"43","author":"Ickowicz","year":"2022","journal-title":"Subst Abus"},{"key":"2025121220304263000_13.5.e068729.54","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.107547","article-title":"Preference for drugs containing fentanyl from a cross-sectional survey of people who use illicit opioids in three United States cities","volume":"204","author":"Morales","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"2025121220304263000_13.5.e068729.55","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109109","article-title":"The use of diverted pharmaceutical opioids is associated with reduced risk of fentanyl exposure among people using unregulated drugs in Vancouver, Canada","volume":"228","author":"Socias","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2025121220304263000_13.5.e068729.56","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108418","article-title":"Examining factors that shape use and access to diverted prescription opioids during an overdose crisis: A qualitative study in Vancouver, Canada","volume":"130","author":"Bardwell","year":"2021","journal-title":"J Subst Abuse Treat"},{"key":"2025121220304263000_13.5.e068729.57","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0b013e3182034e31"},{"key":"2025121220304263000_13.5.e068729.58","doi-asserted-by":"crossref","DOI":"10.1186\/s12954-021-00535-y","article-title":"It\u2019s like \u2018liquid handcuffs: the effects of take-home dosing policies on methadone maintenance treatment (MMT) patients\u2019 lives","volume":"18","author":"Frank","year":"2021","journal-title":"Harm Reduct J"},{"key":"2025121220304263000_13.5.e068729.59","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2013.0179"},{"key":"2025121220304263000_13.5.e068729.60","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1080\/10826084.2019.1653324","article-title":"Patient barriers and Facilitators to medications for opioid use disorder in primary care: an in-depth qualitative survey on buprenorphine and extended-release Naltrexone","volume":"54","author":"Tofighi","year":"2019","journal-title":"Substance Use & Misuse"},{"key":"2025121220304263000_13.5.e068729.61","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.drugpo.2018.06.003","article-title":"Developing a patient-reported experience questionnaire with and for people who use drugs: A community engagement process in Vancouver\u2019s downtown Eastside","volume":"59","author":"Olding","year":"2018","journal-title":"Int J Drug Policy"},{"key":"2025121220304263000_13.5.e068729.62","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/add.15115","article-title":"The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine","volume":"116","author":"Farnum","year":"2021","journal-title":"Addiction"},{"key":"2025121220304263000_13.5.e068729.63","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/14789949.2020.1859590","article-title":"Urine drug screening in a Forensic mental health population: frequency and clinical utility in risk management","volume":"32","author":"Penney","year":"2021","journal-title":"J Forensic Psych Psychol"},{"key":"2025121220304263000_13.5.e068729.64","doi-asserted-by":"crossref","DOI":"10.1186\/s12954-021-00572-7","article-title":"Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives","volume":"18","author":"Aronowitz","year":"2021","journal-title":"Harm Reduct J"},{"key":"2025121220304263000_13.5.e068729.65","unstructured":"British Columbia Ministry of Health [creator] . Pharmanet. British Columbia Ministry of health [publisher]. Data Extract. MOH, 2021. Available: http:\/\/www.health.gov.bc.ca\/data"},{"key":"2025121220304263000_13.5.e068729.66","unstructured":"British Columbia Ministry of Health [creator] . Discharge abstract database (hospital separations). British Columbia Ministry of health [publisher]. Data Extract. MOH, 2021. Available: http:\/\/www.health.gov.bc.ca\/data"},{"key":"2025121220304263000_13.5.e068729.67","unstructured":"British Columbia Ministry of Health [creator] . Medical services plan (MSP) payment information file. British Columbia Ministry of health [publisher]. Data Extract. MOH, 2021. Available: http:\/\/www.health.gov.bc.ca\/data"},{"key":"2025121220304263000_13.5.e068729.68","unstructured":"BC Vital Statistics Agency [creator] . Vital Statistics deaths. British Columbia Ministry of health [publisher]. Data Extract. MOH, 2021. Available: http:\/\/www.health.gov.bc.ca\/data"},{"key":"2025121220304263000_13.5.e068729.69","unstructured":"Ministry of Public Safety and Solicitor General (PSSG) [creator] . BC corrections Dataset. British Columbia Ministry of health [publisher]. Data Extract. MOH, 2021. Available: http:\/\/www.health.gov.bc.ca\/data"},{"key":"2025121220304263000_13.5.e068729.70","unstructured":"Perinatal Services BC [creator] . British Columbia perinatal data Registry. British Columbia Ministry of health [publisher]. Data Extract. MOH, 2021. Available: http:\/\/www.health.gov.bc.ca\/data"},{"key":"2025121220304263000_13.5.e068729.71","unstructured":"British Columbia Ministry of Health [creator] . National ambulatory care reporting system (NACRS). British Columbia Ministry of health [publisher]. Data Extract. MOH, 2021. Available: http:\/\/www.health.gov.bc.ca\/data"},{"key":"2025121220304263000_13.5.e068729.72","unstructured":"British Columbia Ministry of Social Development and Poverty Reduction [creator] . Social development and poverty reduction database (SDPR). British Columbia Ministry of health [publisher]. Data Extract. MOH, 2021. Available: http:\/\/www.health.gov.bc.ca\/data"},{"key":"2025121220304263000_13.5.e068729.73","unstructured":"Government of British Columbia . Personal Health Identification. n.d. Available: https:\/\/www2.gov.bc.ca\/gov\/content\/health\/health-drug-coverage\/msp\/bc-residents\/personal-health-identification"},{"key":"2025121220304263000_13.5.e068729.74","unstructured":"Government of British Columbia . Alternative Payments Program. 2018. Available: https:\/\/www2.gov.bc.ca\/gov\/content\/health\/practitioner-professional-resources\/physician-compensation\/alternative-payments-program"},{"key":"2025121220304263000_13.5.e068729.75","unstructured":"Government of Canada . Health Canada to propose regulatory change to enable consideration of applications under the special access programme to facilitate treatment of chronic Relapsing opioid dependence. 2016. Available: https:\/\/www.canada.ca\/en\/health-canada\/news\/2016\/05\/health-canada-to-propose-regulatory-change-to-enable-consideration-of-applications-under-the-special-access-programme-to-facilitate-treatment-of-chronic-relapsing-opioid-dependence.html"},{"key":"2025121220304263000_13.5.e068729.76","doi-asserted-by":"publisher","DOI":"10.1037\/h0037350"},{"key":"2025121220304263000_13.5.e068729.77","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/QAI.0000000000000956","article-title":"When to monitor Cd4 cell count and HIV RNA to reduce mortality and AIDS-defining illness in Virologically suppressed HIV-positive persons on antiretroviral therapy in high-income countries: A prospective observational study","volume":"72","author":"Caniglia","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025121220304263000_13.5.e068729.78","doi-asserted-by":"crossref","DOI":"10.2202\/1557-4679.1212","article-title":"When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data","volume":"6","author":"Cain","year":"2010","journal-title":"Int J Biostat"},{"key":"2025121220304263000_13.5.e068729.79","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1093\/ije\/dyaa057","article-title":"Reflection on modern methods: trial Emulation in the presence of immortal-time bias. assessing the benefit of major surgery for elderly lung cancer patients using observational data","volume":"49","author":"Maringe","year":"2020","journal-title":"Int J Epidemiol"},{"key":"2025121220304263000_13.5.e068729.80","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/ije\/dyaa223","article-title":"Versatility of the clone-Censor-weight approach: response to \"trial Emulation in the presence of immortal-time bias","volume":"50","author":"Zhao","year":"2021","journal-title":"Int J Epidemiol"},{"key":"2025121220304263000_13.5.e068729.81","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.110669"},{"key":"2025121220304263000_13.5.e068729.82","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2006.pto_329.x"},{"key":"2025121220304263000_13.5.e068729.83","doi-asserted-by":"crossref","unstructured":"Lee EW , Wei LJ , Amato DA , et al . Cox-type regression analysis for large numbers of small groups of correlated failure time observations. In: Klein JP , Goel PK , eds. Survival analysis: state of the art. Dordrecht: Springer Netherlands, 1992: 237\u201347. doi:10.1007\/978-94-015-7983-4","DOI":"10.1007\/978-94-015-7983-4_14"},{"key":"2025121220304263000_13.5.e068729.84","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108647","article-title":"Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada","volume":"133","author":"Kurz","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"2025121220304263000_13.5.e068729.85","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-019-00494-6"},{"key":"2025121220304263000_13.5.e068729.86","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-036102","article-title":"Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada","volume":"10","author":"Piske","year":"2020","journal-title":"BMJ Open"},{"key":"2025121220304263000_13.5.e068729.87","unstructured":"Provincial Health Services Authority . Identifying determinants for hospitalization based on healthcare utilization records. 2008."},{"key":"2025121220304263000_13.5.e068729.88","unstructured":"Canadian Institutes of Health Research . Tri-Council policy statement: ethical conduct for research involving humans. 2018."},{"key":"2025121220304263000_13.5.e068729.89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"2025121220304263000_13.5.e068729.90","doi-asserted-by":"crossref","unstructured":"World Health Organization . World health organization model list of essential medicines for children, 8th list, 2021. 2021. doi:10.1530\/ey.19.13.1","DOI":"10.1530\/ey.19.13.1"},{"key":"2025121220304263000_13.5.e068729.91","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-068729","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T04:30:58Z","timestamp":1765600258000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-068729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":91,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,31]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1136\/bmjopen-2022-068729"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-068729","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}